A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia

Tongji Hospital

Status and phase: Unknown; Phase 4

Conditions: 2019-nCoV

Treatments: Drug: Abidol Hydrochloride combined with Interferon atomization; Drug: Abidol hydrochloride

Study type: Interventional

Funder types: Other

Identifiers

NCT04254874

TJ20200131

Details and patient eligibility

About

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1)2019-nCoV nucleic acid test was positive. 2)CT of the lung conformed to the manifestation of viral pneumonia.

Exclusion criteria

1. Patients who meet any of the contraindications in the experimental drug labeling
2. Patients who do not want to participate in this clinical study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 2 patient groups

Abidol hydrochloride

Experimental group

Description:

Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day).

Treatment:

Drug: Abidol hydrochloride

Abidol Hydrochloride combined with Interferon atomization

Experimental group

Description:

Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I.

Treatment:

Drug: Abidol Hydrochloride combined with Interferon atomization